Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
JCXH-105 by Immorna Hangzhou Biotechnology for Herpes Zoster (Shingles): Likelihood of Approval
JCXH-105 is under clinical development by Immorna Hangzhou Biotechnology and currently in Phase I for Herpes Zoster (Shingles). According to...